How do TRIM37 activity and variation relate to difficult breast-cancer outcomes?
A 2020 Cancer Research paper studies oncogenic TRIM37 in chemoresistance and metastatic fate. A 2025 EMBO Reports paper examines rs57141087 in outcomes among Black women. Dr. Tushir-Singh is a coauthor; these publications should be presented as collaborative work led by their listed first and senior authors.
TRIM37 is a protein implicated in tumor biology. The two papers ask distinct mechanistic and human-variation questions.
Evidence and methods
The studies use the distinct model systems, molecular assays and population analyses described in their respective articles. Their claims should not be merged into one causal chain.
2020 mechanistic study
The Cancer Research article links oncogenic TRIM37 to chemoresistance and metastatic phenotypes in TNBC models.
2025 variant study
EMBO Reports examines an rs57141087 association and functional context in Black women with TNBC.
Inside the study
Collaboration boundary
The collaborative breast-cancer work studies TRIM37-associated biology in triple-negative breast cancer models. Authorship documents participation; the paper should be read for the specific contribution and experimental setting.
Interpretation
The two studies address related TRIM37 biology at different evidence levels; neither author position nor coauthorship alone establishes sole program ownership.
Evidence stage
Collaborative, coauthored research. Population associations and experimental mechanisms require their original study boundaries.
Paper and research team
Original records
- Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast CancerCancer research · 2020
- The TRIM37 variant rs57141087 contributes to triple-negative breast cancer outcomes in Black womenEMBO reports · 2025
- Tihagam et al., EMBO Reports (2025) (external link)
- Przanowski et al., Cancer Research (2020) (external link)